BRAF - PDFSEARCH.IO - Document Search Engine

BRAF
Results: 156

#	Item
41	AT13387, an HSP90 inhibitor, is effective in both vemurafenib-sensitive and -resistant melanoma models Ana M. Rodriguez-Lopez, Tomoko Smyth, Jayne Curry, Brent Graham, Rachel McMenamin, John Lyons, Neil Thompson & Nicola Add to Reading List Source URL: astx.com Language: English - Date: 2012-12-13 18:06:00 Oncogenes Organochlorides Organofluorides Sulfonamides Vemurafenib BRAF Hsp90 inhibitors AKT Hsp90 Medicine Chemistry Biology
42	dabrafenib, 50mg and 75mg hard capsules (Tafinlar®) GlaxoSmithKline SMC No. (No[removed]February 2015 Add to Reading List Source URL: www.scottishmedicines.org.uk Language: English Oncology Melanoma Organochlorides Vemurafenib Dacarbazine Ipilimumab BRAF Protein kinase inhibitor End point of clinical trials Chemistry Medicine Organofluorides
43	MSAC Application 1207: Consultation Decision Analytical Protocol (DAP) to guide the assessment of BRAF genetic testing in patients with melanoma for access to proposed PBS-funded GSK2118436 treatment January 2012 Add to Reading List Source URL: www.msac.gov.au Language: English - Date: 2014-11-06 23:50:11 Vemurafenib Cancer Metastasis Protein kinase inhibitor Medicine Melanoma BRAF
44	Public Summary Document Application No. 1172 – BRAF Genetic Testing in patients with melanoma for access to proposed PBS vemurafenib Applicant: Roche Diagnostics Pty. Ltd. Add to Reading List Source URL: www.msac.gov.au Language: English - Date: 2014-11-06 23:49:34 Melanoma Organochlorides Organofluorides Vemurafenib BRAF Sensitivity and specificity High Resolution Melt Positive predictive value Genetic testing Statistics Biology Biostatistics
45	Public Summary Document Application No. 1207 – Testing for V600 status in patients with locally advanced or metastatic melanoma for eligibility for dabrafenib treatment Sponsor/Applicant/s: Add to Reading List Source URL: www.msac.gov.au Language: English - Date: 2014-11-06 23:50:13 Organofluorides Sulfonamides Vemurafenib BRAF Protein kinase inhibitor Pharmaceutical Benefits Scheme Metastasis Melbourne Sports and Aquatic Centre Medicine Melanoma Organochlorides
46	1207: Final Decision Analytical Protocol (DAP) to guide the assessment of BRAF V600 mutation testing in patients with locally advanced or metastatic melanoma for eligibility for dabrafenib treatment Add to Reading List Source URL: www.msac.gov.au Language: English - Date: 2014-11-06 23:50:12 Vemurafenib Metastasis Protein kinase inhibitor Cancer Raf kinase Skin cancer Ipilimumab Medicine Melanoma BRAF
47	Public Summary Document Application No. 1172 – BRAF Genetic Testing in patients with melanoma for access to proposed PBS vemurafenib Applicant: Roche Diagnostics Pty. Ltd. Date of MSAC consideration: 2 August[removed]. Add to Reading List Source URL: www.msac.gov.au Language: English - Date: 2014-11-06 23:49:33 Biotechnology Molecular biology Biostatistics Melanoma BRAF Oncogenes Vemurafenib High Resolution Melt Sensitivity and specificity Statistics Biology Chemistry
48	Future challenges to HTA Policy challenges Prince of Wales clinical school and Lowy cancer research centre Co-dependent technologies Add to Reading List Source URL: www.pbs.gov.au Language: English - Date: 2014-10-01 21:56:49 Organochlorides Organofluorides Amines Quinazolines Lung cancer KRAS Personalized medicine Gefitinib BRAF Medicine Chemistry Organic chemistry
49	Microsoft Word - Consultation DAP_1207_BRAF V600 _GSK2118436_.doc Add to Reading List Source URL: www.msac.gov.au Language: English - Date: 2014-11-06 23:50:13 Melanoma Organochlorides Organofluorides Vemurafenib BRAF Raf kinase Cancer Skin cancer Protein kinase inhibitor Medicine Oncology Oncogenes
50	DOCX Document Add to Reading List Source URL: www.msac.gov.au Language: English - Date: 2014-11-06 23:49:33 Melanoma Organochlorides Sulfonamides Vemurafenib BRAF Melbourne Sports and Aquatic Centre Pharmaceutical Benefits Scheme Mutation testing Cancer Medicine Health Healthcare in Australia

UPDATE